The ups and downs of multiple sclerosis therapeutics

被引：42

作者：

Hohlfeld, R ^{[1
]}

Wiendl, H

机构：

[1] Univ Munich, Klinikum Grosshadern, Inst Clin Neuroimmunol, D-8000 Munich, Germany

[2] Univ Tubingen, Dept Neurol, D-7400 Tubingen, Germany

来源：

ANNALS OF NEUROLOGY | 2001年 / 49卷 / 03期

关键词：

D O I：

10.1002/ana.61

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：281 / 284

页数：4

共 34 条

[1] TNF neutralization in MS - Results of a randomized, placebo-controlled multicenter study [J].

Arnason, BGW ;

Jacobs, G ;

Hanlon, M ;

Clay, BH ;

Noronha, ABC ;

Auty, A ;

Davis, B ;

Nath, A ;

Bouchard, JP ;

Belanger, C ;

Gosselin, F ;

Thibault, M ;

Duquette, P ;

Bourgoin, P ;

DuBois, R ;

Girard, M ;

Ebers, GC ;

Rice, GPA ;

Vandervoort, MK ;

Francis, GS ;

Duncan, L ;

Lapierre, Y ;

Freedman, MS ;

Christie, SN ;

Rabinovitch, HE ;

Patry, D ;

Murphy, WF ;

Peters, S ;

McGuiness, SD ;

Murray, TJ ;

Bhan, V ;

Maxner, CE ;

Van Dorpe, R ;

Oger, JJ ;

Nelson, J ;

Morrison, W ;

Bogle, N ;

Beall, S ;

Vorobeychick, G ;

Hiltbrunner, AV ;

Bock, J ;

Habil ;

Lesslauer, W ;

Li, DKB ;

Paty, DW ;

Zhao, GJ .

NEUROLOGY, 1999, 53 (03) :457-465

[2] Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand [J].

Bielekova, B ;

Goodwin, B ;

Richert, N ;

Cortese, I ;

Kondo, T ;

Afshar, G ;

Gran, B ;

Eaton, J ;

Antel, J ;

Frank, JA ;

McFarland, HF ;

Martin, R .

NATURE MEDICINE, 2000, 6 (10) :1167-1175

[3] Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS [J].

Calabresi, PA ;

Fields, NS ;

Maloni, HW ;

Hanham, A ;

Carlino, J ;

Moore, J ;

Levin, MC ;

Dhib-Jalbut, S ;

Tranquill, LR ;

Austin, H ;

McFarland, HF ;

Racke, MK .

NEUROLOGY, 1998, 51 (01) :289-292

[4] European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis [J].

Comi, G ;

Filippi, M ;

Wolinsky, JS .

ANNALS OF NEUROLOGY, 2001, 49 (03) :290-297

[5] Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis [J].

Duda, PW ;

Schmied, MC ;

Cook, SL ;

Krieger, JI ;

Hafler, DA .

JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (07) :967-976

[6]

FARINA C, 2001, IN PRESS BRAIN

[7] Whole brain volume changes in patients with progressive MS treated with cladribine [J].

Filippi, M ;

Rovaris, M ;

Iannucci, G ;

Mennea, S ;

Sormani, MP ;

Comi, G .

NEUROLOGY, 2000, 55 (11) :1714-1718

[8] The effect of cladribine on T1 'black hole' changes in progressive MS [J].

Filippi, M ;

Rovaris, M ;

Rice, GPA ;

Sormani, MP ;

Iannucci, G ;

Giacomotti, L ;

Comi, G .

JOURNAL OF THE NEUROLOGICAL SCIENCES, 2000, 176 (01) :42-44

[9]

FRANCIS G, 1997, ANN NEUROL, V42, P467

[10] A phase I trial of solubilized DR2:MBp84-102 (AG284) in multiple sclerosis [J].

Goodkin, DE ;

Shulman, M ;

Winkelhake, MJ ;

Waubant, E ;

Andersson, PB ;

Stewart, T ;

Nelson, S ;

Fischbein, N ;

Coyle, PK ;

Frohman, E ;

Jacobs, L ;

Holcenberg, J ;

Lee, M ;

Mocci, S .

NEUROLOGY, 2000, 54 (07) :1414-1420

← 1 2 3 4 →